Natural products in anti-tuberculosis host-directed therapy
Given that the disease progression of tuberculosis (TB) is primarily related to the host’s immune status, it has been gradually realized that chemotherapy that targets the bacteria may never, on its own, wholly eradicate Mycobacterium tuberculosis, the causative agent of TB. The concept of host-dire...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-02-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223018851 |
| _version_ | 1797324444746645504 |
|---|---|
| author | Xuejiao Huang Douglas B. Lowrie Xiao-Yong Fan Zhidong Hu |
| author_facet | Xuejiao Huang Douglas B. Lowrie Xiao-Yong Fan Zhidong Hu |
| author_sort | Xuejiao Huang |
| collection | DOAJ |
| description | Given that the disease progression of tuberculosis (TB) is primarily related to the host’s immune status, it has been gradually realized that chemotherapy that targets the bacteria may never, on its own, wholly eradicate Mycobacterium tuberculosis, the causative agent of TB. The concept of host-directed therapy (HDT) with immune adjuvants has emerged. HDT could potentially interfere with infection and colonization by the pathogens, enhance the protective immune responses of hosts, suppress the overwhelming inflammatory responses, and help to attain a state of homeostasis that favors treatment efficacy. However, the HDT drugs currently being assessed in combination with anti-TB chemotherapy still face the dilemmas arising from side effects and high costs. Natural products are well suited to compensate for these shortcomings by having gentle modulatory effects on the host immune responses with less immunopathological damage at a lower cost. In this review, we first summarize the profiles of anti-TB immunology and the characteristics of HDT. Then, we focus on the rationale and challenges of developing and implementing natural products-based HDT. A succinct report of the medications currently being evaluated in clinical trials and preclinical studies is provided. This review aims to promote target-based screening and accelerate novel TB drug discovery. |
| first_indexed | 2024-03-08T05:56:13Z |
| format | Article |
| id | doaj.art-ff6141da4c0b4a279d3d0dbd51c3f685 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-03-08T05:56:13Z |
| publishDate | 2024-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-ff6141da4c0b4a279d3d0dbd51c3f6852024-02-05T04:31:01ZengElsevierBiomedicine & Pharmacotherapy0753-33222024-02-01171116087Natural products in anti-tuberculosis host-directed therapyXuejiao Huang0Douglas B. Lowrie1Xiao-Yong Fan2Zhidong Hu3Shanghai Public Health Clinical Center & Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, Shanghai 201508, ChinaShanghai Public Health Clinical Center & Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, Shanghai 201508, ChinaCorresponding authors.; Shanghai Public Health Clinical Center & Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, Shanghai 201508, ChinaCorresponding authors.; Shanghai Public Health Clinical Center & Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, Shanghai 201508, ChinaGiven that the disease progression of tuberculosis (TB) is primarily related to the host’s immune status, it has been gradually realized that chemotherapy that targets the bacteria may never, on its own, wholly eradicate Mycobacterium tuberculosis, the causative agent of TB. The concept of host-directed therapy (HDT) with immune adjuvants has emerged. HDT could potentially interfere with infection and colonization by the pathogens, enhance the protective immune responses of hosts, suppress the overwhelming inflammatory responses, and help to attain a state of homeostasis that favors treatment efficacy. However, the HDT drugs currently being assessed in combination with anti-TB chemotherapy still face the dilemmas arising from side effects and high costs. Natural products are well suited to compensate for these shortcomings by having gentle modulatory effects on the host immune responses with less immunopathological damage at a lower cost. In this review, we first summarize the profiles of anti-TB immunology and the characteristics of HDT. Then, we focus on the rationale and challenges of developing and implementing natural products-based HDT. A succinct report of the medications currently being evaluated in clinical trials and preclinical studies is provided. This review aims to promote target-based screening and accelerate novel TB drug discovery.http://www.sciencedirect.com/science/article/pii/S0753332223018851Natural productHost-directed therapyTuberculosisImmune responseAdjunctive therapy |
| spellingShingle | Xuejiao Huang Douglas B. Lowrie Xiao-Yong Fan Zhidong Hu Natural products in anti-tuberculosis host-directed therapy Biomedicine & Pharmacotherapy Natural product Host-directed therapy Tuberculosis Immune response Adjunctive therapy |
| title | Natural products in anti-tuberculosis host-directed therapy |
| title_full | Natural products in anti-tuberculosis host-directed therapy |
| title_fullStr | Natural products in anti-tuberculosis host-directed therapy |
| title_full_unstemmed | Natural products in anti-tuberculosis host-directed therapy |
| title_short | Natural products in anti-tuberculosis host-directed therapy |
| title_sort | natural products in anti tuberculosis host directed therapy |
| topic | Natural product Host-directed therapy Tuberculosis Immune response Adjunctive therapy |
| url | http://www.sciencedirect.com/science/article/pii/S0753332223018851 |
| work_keys_str_mv | AT xuejiaohuang naturalproductsinantituberculosishostdirectedtherapy AT douglasblowrie naturalproductsinantituberculosishostdirectedtherapy AT xiaoyongfan naturalproductsinantituberculosishostdirectedtherapy AT zhidonghu naturalproductsinantituberculosishostdirectedtherapy |